On Friday, Wells Fargo updated its price target for Medtronic , Inc. (NYSE:MDT), increasing it from $102.00 to $105.00, while maintaining an Overweight rating on the stock. This adjustment follows Medtronic's fourth fiscal quarter revenue surpassing expectations.
Medtronic reported a fourth fiscal quarter 2024 revenue of $8.59 billion, marking a 5.4% organic growth, which topped both the consensus estimate of $8.45 billion and Wells Fargo's own estimate of $8.43 billion.
The company's performance also exceeded its prior guidance of 4.0-4.5% growth. The earnings per share (EPS) for the quarter came in at $1.46, slightly above the consensus estimate of $1.45 and Wells Fargo's estimate.
The analyst noted that the EPS beat, although modest, was influenced by higher total revenue. However, the operating margin was lower than expected, coming in at 26.9% compared to Wells Fargo's estimate of 27.7%. This was attributed to increased operational expenditures, with the company citing higher sales incentives as a contributing factor.
Medtronic's latest financial results demonstrate its ability to outperform market expectations in terms of revenue. The slight discrepancy in EPS and operating margin highlights the impact of operational costs on the company's profitability.
InvestingPro Insights
Following the upbeat fiscal report from Medtronic, Inc. (NYSE:MDT), the latest real-time data from InvestingPro aligns with the positive sentiment from Wells Fargo. Medtronic's market capitalization stands at a robust $108.06 billion, underscoring its significant presence in the healthcare equipment and supplies industry. The company's P/E ratio is currently at 31.07, indicating a premium valuation relative to its earnings. However, when looking at the adjusted P/E ratio for the last twelve months as of Q3 2024, it softens to 21.0, which may appeal to investors seeking a more reasonable entry point based on historical earnings.
InvestingPro Tips further enhance the investment thesis, spotlighting Medtronic's high shareholder yield and a track record of raising dividends for 10 consecutive years, with dividend payments maintained for an impressive 48 years. This consistency reflects a strong commitment to returning value to shareholders. Additionally, Medtronic's stock is known for its low price volatility, providing a level of stability in an investor's portfolio.
For those considering a deeper dive into Medtronic's investment potential, InvestingPro offers additional insights and metrics, including a total of 9 more InvestingPro Tips available on their platform. Interested investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which could provide valuable context to Medtronic’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.